http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 02 Sep 2026 07:04:23 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Telix+Pharmaceuticals+Ltd+%28TLX%29/27015542.html <p>H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $20.00 price target on Telix Pharmaceuticals Ltd (NASDAQ: TLX).</p><p>The analyst commented: "Yesterday, Telix announced that it has completed enrollment (350 patients) in the Phase 3 BiPASS trial, which is evaluating Illuccix and Gozellix + MRI vs. SOC for detection of prostate cancers, and that it has also aligned with the FDA on a New Drug Application (NDA) pathway for BiPASS that, if approved, would support reimbursement as a new product and broaden patient access. In the current diagnosis paradigm, men with elevated prostate-specific antigen (PSA) values can be recommended for http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Telix+Pharmaceuticals+Ltd+%28TLX%29/27015542.html Wed, 02 Sep 2026 07:04:23 -0400 TLX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Jun+30/26952334.html si-local-file:///var/storage/secattach/20260820/26952334.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Jun+30/26952334.html Thu, 20 Aug 2026 06:04:00 -0400 O.31276474 TLPPF TLX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Jun+30/26952334.html si-local-file:///var/storage/secattach/20260820/26952334.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Jun+30/26952334.html Thu, 20 Aug 2026 06:04:00 -0400 O.31276474 TLPPF TLX http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Jun+30/26952334.html si-local-file:///var/storage/secattach/20260820/26952334.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Telix+Pharmaceuticals+++++For%3A+Jun+30/26952334.html Thu, 20 Aug 2026 06:04:00 -0400 O.31276474 TLPPF TLX http://www.streetinsider.com/Trader+Talk/Citi+on+Telix+Pharmaceuticals+Ltd+%28TLX%29%3A+%27Opens+30-Day+Upside+Catalyst+Watch%27/26952009.html <p>Citi analyst Laura Sutcliffe reiterated a Buy rating and $22.00 price target on Telix Pharmaceuticals Ltd (NASDAQ: TLX)</p><ul><li>Opens 30-Day Upside Catalyst Watch</li></ul><p>For an analyst ratings summary and ratings history on Telix Pharmaceuticals Ltd <a href="http://www.streetinsider.com/rating_history.php?q=TLX">click here</a>. For more ratings news on Telix Pharmaceuticals Ltd <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TLX&amp;type=analyst">click here</a>.</p><p>Shares of Telix Pharmaceuticals Ltd closed at $12.12 yesterday.</p> http://www.streetinsider.com/Trader+Talk/Citi+on+Telix+Pharmaceuticals+Ltd+%28TLX%29%3A+%27Opens+30-Day+Upside+Catalyst+Watch%27/26952009.html Thu, 20 Aug 2026 04:58:17 -0400 TLX http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Press+Releases/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html <p align="justify">MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces its financial results for the period ended June 30, 2026.</p> <p align="justify"><strong>H1 2026 key results</strong></p> <p align="justify"><strong>Group performance</strong><strong>1</strong><strong>: Double-digit revenue growth and gross margin improvement</strong></p> <ul type="disc"><li style="margin-bottom:6pt; text-align:justify;">Group revenue of US$477 million, up 22%2 year-over-year, tracking in line with the upper end of full year guidance of US$950 million to US$970 million.</li><li style="margin-bottom:6pt; text-align:justify;">Group gross margin of 55%, up 2% year-over-year, Precision Medicine gross margin of 65%, up 1% year-over-year, reflecting solid commercial http://www.streetinsider.com/Globe+Newswire/Telix+2026+Half-Year+Results%3A+Strong+Commercial+Execution+and+Momentum+in+Late-Stage+Pipeline/26951621.html Wed, 19 Aug 2026 20:32:00 -0400 A.03080680 A.06822034 A.36051124 A.50217011 O.20026344 O.31276474 O.31712121 O.51342612 O.76446908 TLX TLX